ReviewImmunoTargets and therapy2020
The Emerging Role of IL-17 in the Immune-Pathogenesis of Chronic Spontaneous Urticaria.
Review in ImmunoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Development and validation of a clinically applicable biomarker panel for identifying autoimmune type IIb chronic spontaneous urticaria.The World Allergy Organization journal · 2026Article
- Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines.The Korean journal of internal medicine · 2026Review
- Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms.Asia Pacific allergy · 2026Review
- Cytokine imbalance and immune network endotypes underlying heterogeneous response to omalizumab in chronic spontaneous urticaria.Frontiers in immunology · 2026Article
- Determination of perceived stress, salivary cortisol and interleukin-1β levels and clinical features of chronic urticaria in patients with dermographic urticaria in comparison to patients with chronic spontaneous urticaria and healthy individuals.Frontiers in immunology · 2026Article
- Beyond the Skin: Exploring the Gut-Skin Axis in Chronic Spontaneous Urticaria and Other Inflammatory Skin Diseases.Biomedicines · 2025Review
- Cutaneous reactions to vaccination.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- Levels of serum inflammatory cytokines and their correlations with disease severity in patients with chronic spontaneous urticaria.Postepy dermatologii i alergologii · 2024Article
- Monozygotic triplets with juvenile-onset autoimmunity and 18p microdeletion involvingFrontiers in genetics · 2024Article
- Chronic spontaneous urticaria preceded by localized insulin reactions: case report.SAGE open medical case reports · 2024Article
- Cytokine Profiles of Chronic Urticaria Patients and The Effect of Omalizumab Treatment.Dermatology practical & conceptual · 2023Article
- Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data.Life (Basel, Switzerland) · 2023Review
- Exhaled Nitric Oxide Level in Pharynx Angioedema.Journal of clinical medicine · 2022Article
- The Role of Crosstalk of Immune Cells in Pathogenesis of Chronic Spontaneous Urticaria.Frontiers in immunology · 2022Review
- Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Article
- Chronic spontaneous urticaria: update on pathogenesis and therapeutic implications.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is considered to be an autoimmune disorder (type I and type II) in 50% of all cases. However, autoreactive T cells and their proximity with activated mast cells in the skin of CSU patients are believed to be the primary event in mast cell degranulation. The finding of anti-FcɛRIα on mast cells or IgE autoantibodies against thyroid antigens should be considered to be a consequence of the auto-reactive T cells' recognition of the above-mentioned antigens. Our recent finding of increased Th17 and IL-17 expression in both CD4+ T cells and mast cells in the skin of severe CSU patients is supportive for the major role that T cells perform in the pathogenesis of CSU. Supporting this are numerous previous reports in which increased serum IL-17 was found to be in association with CSU disease severity. The beneficial effect of anti-IL-17A (secukinumab) in CSU patients in whom high dose anti-histamines, recurrent course of steroids and omalizumab fail to achieve a reasonable response should be investigated as a new therapeutic strategy in future studies with a large cohort of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.